Previous 10 | Next 10 |
Ziopharm Oncology (ZIOP) announced that Satyavrat (Sath) Shukla, CFA, CFO, has informed the company of his intention to step down from the role effective Dec. 31, 2020 to pursue another opportunity.The company has initiated a search for a new CFO. For further details see: Ziopharm Oncol...
BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that Satyavrat “Sath” Shukla, CFA, Chief Financial Officer, has informed the Company of his intention to step down f...
Clarifies That Decision to Extend Consent Goal Date to December 15 Stems From a Proxy Advisory Firm Improperly Executing Shareholder Votes Emphasizes Ziopharm Possessed Complete Line of Sight Into Improperly Executed Votes Prior to Issuing its Disingenuous Friday Night P...
Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with th...
Recommends A gainst E lecting WaterMill Nominee Jaime Vieser Ziopharm Continues to Recommend that Shareholders Support Company’s Strong Progress by Return ing the GREEN Consent Revocation Card BOSTON, Dec. 10, 2020...
Cites Numerous Instances of Ziopharm Continuing to Dismiss Investor Feedback and Disseminate Blatant Distortions, Including Regarding the Company’s Engagement With WaterMill Highlights Concerning Interlocks That Still Exist Among Current and Recently-Departed Boar...
Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates Concerns About Professional Past of WaterMill Nominee ...
A Leading Proxy Advisory Firm Recommends FOR All Five Proposals on the WHITE Consent Card, Including Electing WaterMill’s Three-Member Slate and Removing Four Incumbent Directors Report Issued by Glass Lewis Notes Shareholders “Have Ample Cause at This ...
Highlights That Director Candidate Holger Weis Continues to Receive Public Endorsements From Highly-Respected Biotechnology Leaders, Including Former DemeRx Board Members Notes That Mr. Weis’ Former Chairman at DemeRx Sees “no Merit to any of the Unsubstant...
ISS Acknowledges Ziopharm’s Outperformance of its Peer Group During Chairman Scott Tarriff’s Tenure Court Filings R aise Concerns About Professional Past of WaterMill Nominee Holger Weis Ziopharm Recommends Sh...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...